AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling
Phase 3
Completed
- Conditions
- Bipolar Disorder
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT00254774
- Locations
- 🇩🇪
Research Site, München, Germany
Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients
Phase 2
Completed
- Conditions
- Borderline Personality Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00254748
- Locations
- 🇳🇱
Research Site, Veghel, Netherlands
The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT00254800
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo - Exenatide - Exenatide
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13
- Registration Number
- NCT00254254
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Safety and Efficacy of Seroquel in First Episode Schizophrenia
Phase 4
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00254241
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study of CP-675,206 in Refractory Melanoma
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 251
- Registration Number
- NCT00254579
- Locations
- 🇬🇧
Research Site, Newcastle Upon Tyne, United Kingdom
🇺🇸Pfizer Investigational Site, Columbus, Ohio, United States
DIabetic Retinopathy Candesartan Trials
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4717
- Registration Number
- NCT00252694
DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2009-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1600
- Registration Number
- NCT00252863
- Locations
- 🇩🇪
Research Site, Zwickau, Germany
Diabetic Retinopathy Candesartan Trials
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5238
- Registration Number
- NCT00252733
- Locations
- 🇩🇰
Research Site, Odense, Denmark
A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
Phase 2
Withdrawn
- Conditions
- Breast Cancer
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00252811
- Locations
- 🇮🇹
Research Site, Milan, Italy
© Copyright 2025. All Rights Reserved by MedPath